IGF-1 Trial Initiated to Assess Efficacy in Slowing Amyotrophic Lateral Sclerosis Progression

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease marked by the progressive and selective loss of motor neurons in the brain and spinal cord, leading to debilitating muscle weakness and paralysis. Current therapeutic options are limited, failing to significantly halt disease progression or improve long-term outcomes for patients. Insulin-like Growth Factor-1 (IGF-1) signaling pathways are critical for maintaining muscle mass and share common regulatory steps with insulin signaling, both of which are implicated in ALS pathology and progression. Investigating IGF-1 offers a promising avenue to address the urgent unmet need for effective disease-modifying treatments in ALS.

This multicenter clinical study is designed to evaluate the therapeutic potential of IGF-1 in patients with Amyotrophic Lateral Sclerosis (ALS). Participants will be enrolled and subsequently followed for a period of 2 years. The study employs a randomized, placebo-controlled design, where patients will receive either the active IGF-1 compound or a placebo. Clinical examinations and assessments of progressive weakness will be conducted at approximately 6-month intervals throughout the study duration to monitor disease progression and treatment effects.